33 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
15 Mar 22
Regulation FD Disclosure
9:32am
) and placebo for once daily oral dosing for 6 mo (Schema 2). Endpoints include safety, cognitive function, as measured by the AD Assessment Scale- Cognitive
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
16 Jun 22
Regulation FD Disclosure
7:08am
the efficacy of CT1812 in restoring synaptic function through quantitative EEG, as reflected by relative theta power Assessment of brain wave activity
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
function through quantitative EEG, as reflected by relative theta power Assessment of brain wave activity via quantitative EEG SEQUEL (COG0202) Day 0 4 weeks
S-1
nv190x1w j9c5
19 Jul 21
IPO registration
7:02am
424B4
n9aqzp
12 Oct 21
Prospectus supplement with pricing info
4:11pm
DRS/A
hjnwrj5 10r4
23 Jun 21
Draft registration statement (amended)
12:00am
424B4
zwigl
14 Nov 22
Prospectus supplement with pricing info
6:02am
10-K
2wb01hjl8ysz eew
30 Mar 22
Annual report
7:40am
S-1
EX-10.4
d1xf4k fpxo1v
19 Jul 21
IPO registration
7:02am
DRS
EX-10.4
o7dcybjyrz
7 May 21
Draft registration statement
12:00am
DEF 14A
0c3f9 q28c
25 Apr 22
Definitive proxy
5:28pm
DRS
n77eq1lgsolr
7 May 21
Draft registration statement
12:00am